.png)
As Pfizer backs out of hemophilia gene therapy space, CSL hopes Hemgenix is here to stay
After Pfizer let limited patient interest get the best of its hemophilia B gene therapy ambitions and discontinued Beqvez, CSL Behring naturally faced the question of whether it can hold its ground with Hemgenix.
After Pfizer let limited patient interest get the best of its hemophilia B gene therapy ambitions and discontinued Beqvez, CSL Behring naturally faced the question of whether it can hold its ground with Hemgenix.
